Physician profile
Anna Kent
NPI 1104189612
$2,992.12
in general payments reported to CMS, 2019-2025
25 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 98% of Hospice and Palliative Medicine (Family Medicine) providers received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $164 · 2024: $1,235 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $567.22 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $533.64 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $346.40 | 2023-2025 | |
| Lilly USA, LLC | $281.84 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $196.00 | 2024-2025 | |
| Glaxosmithkline, LLC. | $176.12 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $110.10 | 2025 | Jynarque, Rexulti |
| Phathom Pharmaceuticals, INC. | $81.92 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $77.35 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $70.27 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $67.97 | 2024-2025 | Eliquis, Camzyos |
| Cequr Corporation | $62.67 | 2025 | Cequr Simplicity |
| Astellas Pharma US INC | $52.35 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $51.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.41 | 2024-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.52 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $38.35 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $32.91 | 2023-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.09 | 2025 | Xifaxan |
| Amgen INC. | $30.26 | 2024 | Otezla, Repatha |
| Daiichi Sankyo INC. | $22.32 | 2023 | Injectafer |
| Averitas Pharma INC. | $22.06 | 2025 | Qutenza |
| Ferring Pharmaceuticals INC. | $18.92 | 2025 | Euflexxa |
| Merck Sharp & Dohme LLC | $15.14 | 2024 | Vaxelis, Proquad, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $13.94 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.